Stocks-BBIO-Bridgebio Pharma Inc

BBIO Bridgebio Pharma Inc

0 0 (0%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2022: Bridgebio Pharma Inc's revenues increased by 11.38% and amounted to 77.65M. Net income increased by 17.36% to -484.65M. Net assets decreased by 43.83% to -1.24B and EPS increased from -3.90 to -3.26.
BBIO's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
22.95%
Net Profit Margin
-1,877.20%
Operating Margin
-5,773.47%
Return On Investment
-75.84%